News
Scientastic festival held in Valais for the first time
Published:01.05.17 — EPFL's Valais Wallis campus in Sion hosted the school’s third annual science festival this past weekend, drawing a large public turnout. 4100 visitors seized the opportunity.
Control of molecular motion by metal-plated 3D-printed plastic pieces
Published:28.04.17 — EPFL scientists have combined 3D-printing with electroplating to easily produce high-quality metal electrodes that can be used as a molecular beam-splitter.
A new EPFL incubator for education technology
Published:27.04.17 — EPFL’s new Swiss EdTech Collider will be home to around 30 startups involved in developing new education technologies. This coworking space, which is being inaugurated today, will give these companies the chance to enhance their visibility among both clients and investors and to generate synergies. The startups will also have the opportunity to become involved in the cutting-edge research conducted by EPFL professors who specialize in education technology.
Light can improve perovskite solar cell performance
Published:27.04.17 — Publishing in Nature, EPFL scientists show how light affects perovskite film formation in solar cells, which is a critical factor in using them for cost-effective and energy-efficient photovoltaics.
A new sensor increases smartwatch battery life five times
Published:26.04.17 — Nearly 80% of the battery power in smartwatches is used up by the heart-rate monitor. But a new generation of sensors developed by EPFL startup ActLight consumes five times less energy. They have been tested and calibrated, and are now ready to be mass-produced for use in new models.
A simplified fabrication process for high efficiency solar cells
Published:25.04.17 — A team of EPFL and CSEM researchers in Neuchâtel presents in Nature Energy a new astonishing method of creating crystalline solar cells with electrical contacts at the rear, suppressing all shadowing at the front. Thanks to the new inexpensive approach, the fabrication process is strongly simplified with efficiencies in the laboratory already surpassing 23%.
EPFL non-profit iM4TB awarded $2.45m for anti-TB drug clinical trials
Published:21.04.17 — The Bill & Melinda Gates foundation has awarded EPFL-based non-profit iM4TB $2.45 million to take their innovative anti-tuberculosis drug PBTZ169 into clinical trials.
Are you sure you want to import this news into ?
This news will be sent to its subscribers.